Metastatic or locally advanced pancreatic cancer research hub

A phase 1, open-label, dose-escalation and dose-expansion study evaluating the safety, feasability and efficacy of ODI-2001 vaccine, a personalized immunotherapy, in patients with metastatic or locally advanced colon cancer of pancreatic cancer

This study is testing a new, personalised vaccine called ODI-2001 for people with advanced bowel or pancreatic cancer. Researchers want to see if it's safe, how well it works, and what dose is best. It's an early-stage study to understand this new treatment better.